{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:31:18Z","timestamp":1790937078194,"version":"4.1.0"},"reference-count":207,"publisher":"Portland Press Ltd.","issue":"6","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:p>Decades of research into the Hippo signaling pathway have greatly advanced our understanding of its roles in organ growth, tissue regeneration, and tumorigenesis. The Hippo pathway is frequently dysregulated in human cancers and is recognized as a prominent cancer signaling pathway. Hence, the Hippo pathway represents an ideal molecular target for cancer therapies. This review will highlight recent advancements in targeting the Hippo pathway for cancer treatment and discuss the potential opportunities for developing new therapeutic modalities.<\/jats:p>","DOI":"10.1042\/bst20240244","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T14:27:53Z","timestamp":1733495273000},"page":"2399-2413","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances towards potential cancer therapeutics targeting Hippo signaling"],"prefix":"10.1042","volume":"52","author":[{"given":"Rui","family":"Zhu","sequence":"first","affiliation":[{"name":"Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Jiao","sequence":"additional","affiliation":[{"name":"Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-9335","authenticated-orcid":false,"given":"Fa-Xing","family":"Yu","sequence":"additional","affiliation":[{"name":"Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2024121916311234200_BST-2024-0244CC1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The hippo signaling pathway in development and cancer","volume":"19","year":"2010","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.tcb.2012.04.006","article-title":"The Hippo signaling pathway and stem cell biology","volume":"22","year":"2012","journal-title":"Trends Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.210773.112","article-title":"The Hippo pathway: regulators and regulations","volume":"27","year":"2013","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-genet-120417-031621","article-title":"The Hippo signaling network and its biological functions","volume":"52","year":"2018","journal-title":"Annu. Rev. Genet."},{"key":"2024121916311234200_BST-2024-0244CC5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2022.04.001","article-title":"The unfolding of the Hippo signaling pathway","volume":"487","year":"2022","journal-title":"Dev. Biol."},{"key":"2024121916311234200_BST-2024-0244CC6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1101\/gad.9.5.534","article-title":"The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation","volume":"9","year":"1995","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1242\/dev.121.4.1053","article-title":"Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase","volume":"121","year":"1995","journal-title":"Development"},{"key":"2024121916311234200_BST-2024-0244CC8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.274027.115","article-title":"Mechanisms of Hippo pathway regulation","volume":"30","year":"2016","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: biology and pathophysiology","volume":"88","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"2024121916311234200_BST-2024-0244CC10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/abbs\/gmaa048","article-title":"Regulation and functions of the Hippo pathway in stemness and differentiation","volume":"52","year":"2020","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2024121916311234200_BST-2024-0244CC11","doi-asserted-by":"publisher","first-page":"113926","DOI":"10.1016\/j.celrep.2024.113926","article-title":"The Hippo signaling pathway in development and regeneration","volume":"43","year":"2024","journal-title":"Cell Rep."},{"key":"2024121916311234200_BST-2024-0244CC12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","article-title":"The biology of YAP\/TAZ: hippo signaling and beyond","volume":"94","year":"2014","journal-title":"Physiol. Rev."},{"key":"2024121916311234200_BST-2024-0244CC13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41568-019-0168-y","article-title":"YAP and TAZ: a signalling hub of the tumour microenvironment","volume":"19","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.262816.115","article-title":"A YAP\/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis","volume":"29","year":"2015","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","article-title":"The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP","volume":"122","year":"2005","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cub.2008.02.034","article-title":"SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila","volume":"18","year":"2008","journal-title":"Curr. Biol."},{"key":"2024121916311234200_BST-2024-0244CC17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.devcel.2008.01.007","article-title":"The TEAD\/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway","volume":"14","year":"2008","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.devcel.2008.01.006","article-title":"The TEAD\/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control","volume":"14","year":"2008","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC19","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","year":"2008","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ncb1050","article-title":"Hippo promotes proliferation arrest and apoptosis in the Salvador\/Warts pathway","volume":"5","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0092-8674(03)00557-9","article-title":"The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis","volume":"114","year":"2003","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0092-8674(03)00549-X","article-title":"Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts","volume":"114","year":"2003","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC23","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1101\/gad.1134003","article-title":"The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis","volume":"17","year":"2003","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ncb1051","article-title":"The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila","volume":"5","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.devcel.2014.09.012","article-title":"The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila","volume":"31","year":"2014","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC26","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.1038\/ncomms9357","article-title":"MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway","volume":"6","year":"2015","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.devcel.2015.08.014","article-title":"Identification of Happyhour\/MAP4K as alternative Hpo\/Mst-like kinases in the Hippo kinase cascade","volume":"34","year":"2015","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.1843810","article-title":"A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)","volume":"24","year":"2010","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","article-title":"Elucidation of a universal size-control mechanism in Drosophila and mammals","volume":"130","year":"2007","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC30","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","article-title":"Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control","volume":"21","year":"2007","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ydbio.2009.10.046","article-title":"Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms","volume":"337","year":"2010","journal-title":"Dev. Biol."},{"key":"2024121916311234200_BST-2024-0244CC32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ncb1339","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.devcel.2009.12.013","article-title":"The WW domain protein Kibra acts upstream of Hippo in Drosophila","volume":"18","year":"2010","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.devcel.2009.12.011","article-title":"Kibra is a regulator of the Salvador\/Warts\/Hippo signaling network","volume":"18","year":"2010","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.devcel.2009.12.012","article-title":"Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded","volume":"18","year":"2010","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC36","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1242\/dev.00168","article-title":"Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila","volume":"129","year":"2002","journal-title":"Development"},{"key":"2024121916311234200_BST-2024-0244CC37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0092-8674(02)00824-3","article-title":"Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines","volume":"110","year":"2002","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cell.2004.12.036","article-title":"Control of cell proliferation and apoptosis by mob as tumor suppressor, mats","volume":"120","year":"2005","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC39","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1074\/jbc.C110.212621","article-title":"Hippo pathway-independent restriction of TAZ and YAP by angiomotin","volume":"286","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2024121916311234200_BST-2024-0244CC40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1101\/gad.2000111","article-title":"Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein","volume":"25","year":"2011","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC41","doi-asserted-by":"publisher","first-page":"e23966","DOI":"10.7554\/eLife.23966","article-title":"Regulation of localization and function of the transcriptional co-activator YAP by angiomotin","volume":"6","year":"2017","journal-title":"Elife"},{"key":"2024121916311234200_BST-2024-0244CC42","doi-asserted-by":"publisher","first-page":"e2400076","DOI":"10.1002\/bies.202400076","article-title":"Angiomotin family proteins in the Hippo signaling pathway","volume":"46","year":"2024","journal-title":"Bioessays"},{"key":"2024121916311234200_BST-2024-0244CC43","doi-asserted-by":"publisher","first-page":"e2121779119","DOI":"10.1073\/pnas.2121779119","article-title":"Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway","volume":"119","year":"2022","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2024121916311234200_BST-2024-0244CC44","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41467-022-28567-3","article-title":"Cell adhesion molecule KIRREL1 is a feedback regulator of Hippo signaling recruiting SAV1 to cell-cell contact sites","volume":"13","year":"2022","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC45","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.molcel.2022.03.027","article-title":"WWC proteins mediate LATS1\/2 activation by Hippo kinases and imply a tumor suppression strategy","volume":"82","year":"2022","journal-title":"Mol. Cell"},{"key":"2024121916311234200_BST-2024-0244CC46","doi-asserted-by":"publisher","first-page":"e112126","DOI":"10.15252\/embj.2022112126","article-title":"Two Hippo signaling modules orchestrate liver size and tumorigenesis","volume":"42","year":"2023","journal-title":"EMBO J."},{"key":"2024121916311234200_BST-2024-0244CC47","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.scib.2023.08.048","article-title":"Reconstructing the Hippo signaling network","volume":"68","year":"2023","journal-title":"Sci. Bull."},{"key":"2024121916311234200_BST-2024-0244CC48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"150","year":"2012","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the roots of cancer","volume":"29","year":"2016","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","article-title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","volume":"23","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC52","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","article-title":"YAP1 increases organ size and expands undifferentiated progenitor cells","volume":"17","year":"2007","journal-title":"Curr. Biol."},{"key":"2024121916311234200_BST-2024-0244CC53","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","article-title":"Hippo pathway activity influences liver cell fate","volume":"157","year":"2014","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC54","doi-asserted-by":"publisher","first-page":"8248","DOI":"10.1073\/pnas.0912203107","article-title":"The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis","volume":"107","year":"2010","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2024121916311234200_BST-2024-0244CC55","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1073\/pnas.0911409107","article-title":"Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression","volume":"107","year":"2010","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2024121916311234200_BST-2024-0244CC56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2009.09.026","article-title":"Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene","volume":"16","year":"2009","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC57","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1101\/gad.1938710","article-title":"Nf2\/Merlin controls progenitor homeostasis and tumorigenesis in the liver","volume":"24","year":"2010","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC58","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-17-3487","article-title":"YAP\/TAZ initiates gastric tumorigenesis via upregulation of MYC","volume":"78","year":"2018","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC59","doi-asserted-by":"publisher","first-page":"e45809","DOI":"10.15252\/embr.201845809","article-title":"YAP and TAZ are essential for basal and squamous cell carcinoma initiation","volume":"19","year":"2018","journal-title":"EMBO Rep."},{"key":"2024121916311234200_BST-2024-0244CC60","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","year":"2012","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC61","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ccell.2018.01.005","article-title":"Programming of Schwann cells by Lats1\/2-TAZ\/YAP signaling drives malignant peripheral nerve sheath tumorigenesis","volume":"33","year":"2018","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","year":"2011","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14348\/molcells.2018.2242","article-title":"The role of Hippo pathway in cancer stem cell biology","volume":"41","year":"2018","journal-title":"Mol. Cells"},{"key":"2024121916311234200_BST-2024-0244CC64","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awac342","article-title":"Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma","volume":"146","year":"2023","journal-title":"Brain"},{"key":"2024121916311234200_BST-2024-0244CC65","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1158\/0008-5472.CAN-13-3569","article-title":"Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties","volume":"74","year":"2014","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.20892\/j.issn.2095-3941.2023.0164","article-title":"The Hippo\/YAP signaling pathway: the driver of cancer metastasis","volume":"20","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"2024121916311234200_BST-2024-0244CC67","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1038\/s41388-022-02344-4","article-title":"YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer","volume":"41","year":"2022","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC68","doi-asserted-by":"publisher","first-page":"14122","DOI":"10.1038\/ncomms14122","article-title":"Fluid shear stress activates YAP1 to promote cancer cell motility","volume":"8","year":"2017","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC69","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41556-018-0138-8","article-title":"Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization","volume":"20","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC70","doi-asserted-by":"publisher","first-page":"114003","DOI":"10.1016\/j.celrep.2024.114003","article-title":"Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity","volume":"43","year":"2024","journal-title":"Cell Rep."},{"key":"2024121916311234200_BST-2024-0244CC71","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1","volume":"78","year":"2018","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/gad.294348.116","article-title":"Single tumor-initiating cells evade immune clearance by recruiting type II macrophages","volume":"31","year":"2017","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers","volume":"20","year":"2014","journal-title":"Nat. Med."},{"key":"2024121916311234200_BST-2024-0244CC74","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.stem.2020.07.003","article-title":"Regenerative reprogramming of the intestinal stem cell state via Hippo signaling suppresses metastatic colorectal cancer","volume":"27","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2024121916311234200_BST-2024-0244CC75","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/s41586-020-03131-5","article-title":"Hippo signalling maintains ER expression and ER(+) breast cancer growth","volume":"591","year":"2021","journal-title":"Nature"},{"key":"2024121916311234200_BST-2024-0244CC76","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1038\/s41467-022-30831-5","article-title":"YAP inhibits ERalpha and ER(+) breast cancer growth by disrupting a TEAD-ERalpha signaling axis","volume":"13","year":"2022","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","article-title":"A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer","volume":"25","year":"2014","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC78","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.04.004","article-title":"Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2","volume":"31","year":"2017","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC79","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccell.2015.05.005","article-title":"ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors","volume":"27","year":"2015","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC80","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/embj.201386082","article-title":"Tumor-propagating cells and Yap\/Taz activity contribute to lung tumor progression and metastasis","volume":"33","year":"2014","journal-title":"EMBO J."},{"key":"2024121916311234200_BST-2024-0244CC81","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","year":"2018","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC82","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","year":"2016","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC83","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","year":"1993","journal-title":"Nature"},{"key":"2024121916311234200_BST-2024-0244CC84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","year":"2016","journal-title":"Nat. Genet."},{"key":"2024121916311234200_BST-2024-0244CC85","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"2024121916311234200_BST-2024-0244CC86","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","year":"2022","journal-title":"Br. J. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC87","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-11-523","article-title":"Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma","volume":"11","year":"2011","journal-title":"BMC Cancer"},{"key":"2024121916311234200_BST-2024-0244CC88","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC89","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1038\/s41467-022-31399-w","article-title":"Inactivation of the Hippo tumor suppressor pathway promotes melanoma","volume":"13","year":"2022","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC90","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive molecular characterization of the Hippo signaling pathway in cancer","volume":"25","year":"2018","journal-title":"Cell Rep."},{"key":"2024121916311234200_BST-2024-0244CC91","doi-asserted-by":"publisher","first-page":"12505","DOI":"10.1073\/pnas.0605207103","article-title":"Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers","volume":"103","year":"2006","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2024121916311234200_BST-2024-0244CC92","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","year":"2006","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC93","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/gcc.22073","article-title":"Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma","volume":"52","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"2024121916311234200_BST-2024-0244CC94","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1746-1596-9-131","article-title":"Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases","volume":"9","year":"2014","journal-title":"Diagn. Pathol."},{"key":"2024121916311234200_BST-2024-0244CC95","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/his.12697","article-title":"Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants","volume":"67","year":"2015","journal-title":"Histopathology"},{"key":"2024121916311234200_BST-2024-0244CC96","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.humpath.2017.08.020","article-title":"Multicentric visceral epithelioid hemangioendothelioma, with extremity dermal deposits, unusual late recurrence on the nasal bridge, and TFE3 gene rearrangement","volume":"72","year":"2018","journal-title":"Hum. Pathol."},{"key":"2024121916311234200_BST-2024-0244CC97","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups","volume":"27","year":"2015","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC98","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","article-title":"C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma","volume":"506","year":"2014","journal-title":"Nature"},{"key":"2024121916311234200_BST-2024-0244CC99","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.chembiol.2012.07.005","article-title":"Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP","volume":"19","year":"2012","journal-title":"Chem. Biol."},{"key":"2024121916311234200_BST-2024-0244CC100","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1101\/gad.197582.112","article-title":"Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs)","volume":"26","year":"2012","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC101","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1038\/onc.2014.281","article-title":"Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway","volume":"34","year":"2015","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC102","doi-asserted-by":"publisher","first-page":"e6833","DOI":"10.1371\/journal.pone.0006833","article-title":"Mutational profile of GNAQQ209 in human tumors","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"2024121916311234200_BST-2024-0244CC103","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","year":"2009","journal-title":"Nature"},{"key":"2024121916311234200_BST-2024-0244CC104","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2024121916311234200_BST-2024-0244CC105","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","year":"2014","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC106","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","article-title":"KRAS and YAP1 converge to regulate EMT and tumor survival","volume":"158","year":"2014","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC107","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2019.10.037","article-title":"Yap1 activation enables bypass of oncogenic kras addiction in pancreatic cancer","volume":"179","year":"2019","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC108","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","article-title":"YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response","volume":"158","year":"2014","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC109","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1101\/gad.233676.113","article-title":"A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis","volume":"28","year":"2014","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC110","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1097\/MD.0000000000005768","article-title":"Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome","volume":"96","year":"2017","journal-title":"Medicine"},{"key":"2024121916311234200_BST-2024-0244CC111","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12885-018-4627-8","article-title":"Aberrant promoter methylation of YAP gene and its subsequent downregulation in Indian breast cancer patients","volume":"18","year":"2018","journal-title":"BMC Cancer"},{"key":"2024121916311234200_BST-2024-0244CC112","doi-asserted-by":"publisher","first-page":"586581","DOI":"10.3389\/fcell.2020.586581","article-title":"Hypermethylation of LATS2 promoter and its prognostic value in IDH-mutated low-grade gliomas","volume":"8","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"2024121916311234200_BST-2024-0244CC113","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","year":"2019","journal-title":"Trends Cancer"},{"key":"2024121916311234200_BST-2024-0244CC114","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1038\/onc.2011.8","article-title":"The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene","volume":"30","year":"2011","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC115","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1038\/onc.2010.339","article-title":"YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets","volume":"29","year":"2010","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC116","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/0008-5472.CAN-10-2711","article-title":"Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF","volume":"71","year":"2011","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC117","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1541-7786.MCR-17-0684","article-title":"Identification of Cdk1-LATS-Pin1 as a novel signaling axis in anti-tubulin drug response of cancer cells","volume":"16","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC118","doi-asserted-by":"publisher","first-page":"30053","DOI":"10.18632\/oncotarget.25698","article-title":"miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"2024121916311234200_BST-2024-0244CC119","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ebiom.2018.08.010","article-title":"miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression","volume":"35","year":"2018","journal-title":"EBioMedicine"},{"key":"2024121916311234200_BST-2024-0244CC120","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1158\/0008-5472.CAN-08-2524","article-title":"Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1","volume":"69","year":"2009","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC121","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2016.04.089","article-title":"Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance","volume":"474","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024121916311234200_BST-2024-0244CC122","doi-asserted-by":"publisher","first-page":"51922","DOI":"10.18632\/oncotarget.10458","article-title":"YAP promotes erlotinib resistance in human non-small cell lung cancer cells","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"2024121916311234200_BST-2024-0244CC123","doi-asserted-by":"publisher","first-page":"497","DOI":"10.18632\/genesandcancer.136","article-title":"NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors","volume":"8","year":"2017","journal-title":"Genes Cancer"},{"key":"2024121916311234200_BST-2024-0244CC124","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3892\/or.2018.6630","article-title":"Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells","volume":"40","year":"2018","journal-title":"Oncol. Rep."},{"key":"2024121916311234200_BST-2024-0244CC125","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","year":"2018","journal-title":"Oncologist"},{"key":"2024121916311234200_BST-2024-0244CC126","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2024121916311234200_BST-2024-0244CC127","doi-asserted-by":"publisher","first-page":"1758835920925219","DOI":"10.1177\/1758835920925219","article-title":"Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations","volume":"12","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2024121916311234200_BST-2024-0244CC128","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","year":"2015","journal-title":"Nat. Genet."},{"key":"2024121916311234200_BST-2024-0244CC129","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/jcmm.13593","article-title":"Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma","volume":"22","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"2024121916311234200_BST-2024-0244CC130","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"2024121916311234200_BST-2024-0244CC131","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","year":"2016","journal-title":"Cancer Discov."},{"key":"2024121916311234200_BST-2024-0244CC132","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/onc.2016.288","article-title":"Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma","volume":"36","year":"2017","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC133","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.2147\/OTT.S102733","article-title":"Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer","volume":"9","year":"2016","journal-title":"Onco Targets Ther."},{"key":"2024121916311234200_BST-2024-0244CC134","doi-asserted-by":"publisher","first-page":"28628","DOI":"10.18632\/oncotarget.15614","article-title":"Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2024121916311234200_BST-2024-0244CC135","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1038\/s41598-023-29796-2","article-title":"Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP\/TAZ expression","volume":"13","year":"2023","journal-title":"Sci. Rep."},{"key":"2024121916311234200_BST-2024-0244CC136","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.freeradbiomed.2022.10.323","article-title":"YAP1 silencing attenuated lung injury\/fibrosis but worsened diaphragmatic function by regulating oxidative stress and inflammation response in mice","volume":"193","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"2024121916311234200_BST-2024-0244CC137","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","year":"2024","journal-title":"Nat. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC138","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nchembio.2036","article-title":"Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway","volume":"12","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"2024121916311234200_BST-2024-0244CC139","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","article-title":"Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy","volume":"23","year":"2015","journal-title":"Structure"},{"key":"2024121916311234200_BST-2024-0244CC140","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.Am2023-Ct006","article-title":"First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations","volume":"83","year":"2023","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC141","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","year":"2012","journal-title":"Gene Dev."},{"key":"2024121916311234200_BST-2024-0244CC142","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1158\/1538-7445.Am2024-7575","article-title":"BPI-460372, a covalent, irreversible TEAD inhibitor in Phase I clinical development","volume":"84","year":"2023","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC143","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1158\/1538-7445.Am2023-4964","article-title":"SW-682: a novel TEAD inhibitor for the treatment of cancers bearing mutations in the Hippo signaling pathway","volume":"83","year":"2023","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC144","doi-asserted-by":"publisher","first-page":"14058","DOI":"10.1038\/ncomms14058","article-title":"VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer","volume":"8","year":"2017","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC145","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3892\/or.2019.7370","article-title":"Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K\/Akt\/mTOR pathway","volume":"42","year":"2019","journal-title":"Oncol. Rep."},{"key":"2024121916311234200_BST-2024-0244CC146","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/ml500160m","article-title":"Structure-based design and synthesis of potent cyclic peptides inhibiting the YAP-TEAD protein-protein interaction","volume":"5","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"2024121916311234200_BST-2024-0244CC147","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1096\/fj.14-262980","article-title":"Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides","volume":"29","year":"2015","journal-title":"FASEB J."},{"key":"2024121916311234200_BST-2024-0244CC148","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","article-title":"The emerging roles of YAP and TAZ in cancer","volume":"15","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC149","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s43018-022-00473-z","article-title":"YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches","volume":"4","year":"2023","journal-title":"Nat. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC150","doi-asserted-by":"publisher","first-page":"e18330","DOI":"10.1111\/jcmm.18330","article-title":"YAP\/TAZ-TEAD signalling axis: a new therapeutic target in malignant pleural mesothelioma","volume":"28","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"2024121916311234200_BST-2024-0244CC151","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3892\/or.2019.6956","article-title":"Ubiquitination-deubiquitination in the Hippo signaling pathway (Review)","volume":"41","year":"2019","journal-title":"Oncol. Rep."},{"key":"2024121916311234200_BST-2024-0244CC152","doi-asserted-by":"publisher","first-page":"37159","DOI":"10.1074\/jbc.M110.152942","article-title":"The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFbeta-TrCP E3 ligase","volume":"285","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2024121916311234200_BST-2024-0244CC153","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s13238-019-00674-w","article-title":"USP47-mediated deubiquitination and stabilization of YAP contributes to the progression of colorectal cancer","volume":"11","year":"2020","journal-title":"Protein Cell"},{"key":"2024121916311234200_BST-2024-0244CC154","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41467-019-08334-7","article-title":"Usp7 regulates Hippo pathway through deubiquitinating the transcriptional coactivator Yorkie","volume":"10","year":"2019","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC155","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","year":"2001","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2024121916311234200_BST-2024-0244CC156","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41589-022-00971-2","article-title":"Deubiquitinase-targeting chimeras for targeted protein stabilization","volume":"18","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"2024121916311234200_BST-2024-0244CC157","doi-asserted-by":"publisher","first-page":"e30278","DOI":"10.7554\/eLife.30278","article-title":"SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK","volume":"6","year":"2017","journal-title":"Elife"},{"key":"2024121916311234200_BST-2024-0244CC158","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41556-019-0460-9","article-title":"Publisher Correction: STRIPAK integrates upstream signals to initiate the Hippo kinase cascade","volume":"22","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC159","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1016\/j.celrep.2017.11.076","article-title":"Homeostatic control of Hpo\/MST kinase activity through autophosphorylation-dependent recruitment of the STRIPAK PP2A phosphatase complex","volume":"21","year":"2017","journal-title":"Cell Rep."},{"key":"2024121916311234200_BST-2024-0244CC160","doi-asserted-by":"publisher","first-page":"107860","DOI":"10.1016\/j.celrep.2020.107860","article-title":"MAP4K interactome reveals STRN4 as a key STRIPAK complex component in Hippo pathway regulation","volume":"32","year":"2020","journal-title":"Cell Rep."},{"key":"2024121916311234200_BST-2024-0244CC161","doi-asserted-by":"publisher","first-page":"107311","DOI":"10.1016\/j.jbc.2024.107311","article-title":"Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity","volume":"300","year":"2024","journal-title":"J. Biol. Chem."},{"key":"2024121916311234200_BST-2024-0244CC162","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC163","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","article-title":"The hippo signaling pathway in development and disease","volume":"50","year":"2019","journal-title":"Dev. Cell"},{"key":"2024121916311234200_BST-2024-0244CC164","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","year":"2011","journal-title":"Pathol. Int."},{"key":"2024121916311234200_BST-2024-0244CC165","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.omtm.2022.06.012","article-title":"Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2","volume":"26","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2024121916311234200_BST-2024-0244CC166","unstructured":"Chang, L.S., Flanigan, K., Likhite, S. and Meyer, K. (2024) U.S. Patent Application No. 18\/286,923. https:\/\/www.freepatentsonline.com\/y2024\/0189453.html"},{"key":"2024121916311234200_BST-2024-0244CC167","unstructured":"Yu, F.X., Qi, S. and Zhong, Z. (2023) International Application No. PCT\/CN2023\/086440. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2023193739"},{"key":"2024121916311234200_BST-2024-0244CC168","doi-asserted-by":"publisher","first-page":"101763","DOI":"10.1016\/j.xcrm.2024.101763","article-title":"Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo","volume":"5","year":"2024","journal-title":"Cell Rep. Med."},{"key":"2024121916311234200_BST-2024-0244CC169","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","article-title":"The Hippo pathway kinases LATS1\/2 suppress cancer immunity","volume":"167","year":"2016","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC170","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/s41467-022-28691-0","article-title":"Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER(+) breast cancer","volume":"13","year":"2022","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC171","doi-asserted-by":"publisher","first-page":"e112184","DOI":"10.15252\/embj.2022112184","article-title":"YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth","volume":"42","year":"2023","journal-title":"EMBO J."},{"key":"2024121916311234200_BST-2024-0244CC172","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41467-021-23395-3","article-title":"Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues","volume":"12","year":"2021","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC173","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.stem.2024.03.003","article-title":"NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo","volume":"31","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2024121916311234200_BST-2024-0244CC174","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.semcdb.2012.06.001","article-title":"Regulation of the Hippo pathway by cell architecture and mechanical signals","volume":"23","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"2024121916311234200_BST-2024-0244CC175","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s13046-019-1506-3","article-title":"ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity","volume":"38","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC176","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1101\/gad.219402.113","article-title":"Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation","volume":"27","year":"2013","journal-title":"Genes Dev."},{"key":"2024121916311234200_BST-2024-0244CC177","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.cell.2024.02.007","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"187","year":"2024","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC178","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/onc.2016.224","article-title":"PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis","volume":"36","year":"2017","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC179","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.cell.2013.07.042","article-title":"A mechanical checkpoint controls multicellular growth through YAP\/TAZ regulation by actin-processing factors","volume":"154","year":"2013","journal-title":"Cell"},{"key":"2024121916311234200_BST-2024-0244CC180","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1165\/rcmb.2019-0296OC","article-title":"Screening for YAP inhibitors identifies statins as modulators of fibrosis","volume":"62","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2024121916311234200_BST-2024-0244CC181","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1074\/jbc.RA118.004364","article-title":"SRC tyrosine kinase activates the YAP\/TAZ axis and thereby drives tumor growth and metastasis","volume":"294","year":"2019","journal-title":"J. Biol. Chem."},{"key":"2024121916311234200_BST-2024-0244CC182","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41588-022-01119-7","article-title":"YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis","volume":"54","year":"2022","journal-title":"Nat. Genet."},{"key":"2024121916311234200_BST-2024-0244CC183","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","article-title":"Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4","volume":"24","year":"2018","journal-title":"Nat. Med."},{"key":"2024121916311234200_BST-2024-0244CC184","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1038\/s41388-019-0924-1","article-title":"The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells","volume":"38","year":"2019","journal-title":"Oncogene"},{"key":"2024121916311234200_BST-2024-0244CC185","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.cmet.2018.07.010","article-title":"Interplay between YAP\/TAZ and metabolism","volume":"28","year":"2018","journal-title":"Cell Metab."},{"key":"2024121916311234200_BST-2024-0244CC186","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.tox.2011.01.006","article-title":"Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma","volume":"281","year":"2011","journal-title":"Toxicology"},{"key":"2024121916311234200_BST-2024-0244CC187","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/hep.21743","article-title":"Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"2024121916311234200_BST-2024-0244CC188","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/ncb3389","article-title":"Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth","volume":"18","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC189","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"2024121916311234200_BST-2024-0244CC190","doi-asserted-by":"publisher","first-page":"e0216603","DOI":"10.1371\/journal.pone.0216603","article-title":"Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice","volume":"14","year":"2019","journal-title":"PLoS One"},{"key":"2024121916311234200_BST-2024-0244CC191","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway","volume":"34","year":"2018","journal-title":"Cancer Cell"},{"key":"2024121916311234200_BST-2024-0244CC192","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41467-019-13771-5","article-title":"YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation","volume":"11","year":"2020","journal-title":"Nat. Commun."},{"key":"2024121916311234200_BST-2024-0244CC193","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1021\/acs.jmedchem.1c00804","article-title":"Inhibitors of the Hippo pathway kinases STK3\/MST2 and STK4\/MST1 have utility for the treatment of acute myeloid leukemia","volume":"65","year":"2022","journal-title":"J. Med. Chem."},{"key":"2024121916311234200_BST-2024-0244CC194","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/mmr.2021.12022","article-title":"MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker","volume":"23","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"2024121916311234200_BST-2024-0244CC195","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ymthe.2021.08.029","article-title":"Non-canonical role of Hippo tumor suppressor serine\/threonine kinase 3 STK3 in prostate cancer","volume":"30","year":"2022","journal-title":"Mol. Ther."},{"key":"2024121916311234200_BST-2024-0244CC196","doi-asserted-by":"publisher","first-page":"2192501","DOI":"10.1080\/19490976.2023.2192501","article-title":"YAP and beta-catenin cooperate to drive H. pylori-induced gastric tumorigenesis","volume":"15","year":"2023","journal-title":"Gut Microbes"},{"key":"2024121916311234200_BST-2024-0244CC197","doi-asserted-by":"publisher","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2021-ND11","article-title":"Abstract ND11: the discovery and characterization of ION-537: a next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models","volume":"81","year":"2021","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC198","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","article-title":"YAP\/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma","volume":"27","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC199","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/neuonc\/noab244","article-title":"Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models","volume":"24","year":"2022","journal-title":"Neuro Oncol."},{"key":"2024121916311234200_BST-2024-0244CC200","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","year":"2024","journal-title":"Nat. Cancer"},{"key":"2024121916311234200_BST-2024-0244CC201","doi-asserted-by":"publisher","first-page":"P216","DOI":"10.1158\/1535-7163.TARG-21-P216","article-title":"Abstract P216: IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors","volume":"20","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2024121916311234200_BST-2024-0244CC202","volume-title":"A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","year":"2022"},{"key":"2024121916311234200_BST-2024-0244CC203","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.stem.2020.03.002","article-title":"Lats1\/2 sustain intestinal stem cells and Wnt activation through TEAD-dependent and independent transcription","volume":"26","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2024121916311234200_BST-2024-0244CC204","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1158\/1538-7445.AM2023-4976","article-title":"Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential","volume":"83","year":"2023","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC205","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.1158\/1538-7445.AM2022-5364","article-title":"The TEAD autopalmitoylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models","volume":"82","year":"2022","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC206","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/1538-7445.AM2023-501","article-title":"Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations","volume":"83","year":"2023","journal-title":"Cancer Res."},{"key":"2024121916311234200_BST-2024-0244CC207","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cellsig.2009.12.010","article-title":"Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth","volume":"22","year":"2010","journal-title":"Cell Signal."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/52\/6\/2399\/964293\/bst-2024-0244c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/52\/6\/2399\/964293\/bst-2024-0244c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:31:51Z","timestamp":1734625911000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/52\/6\/2399\/235351\/Advances-towards-potential-cancer-therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":207,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20240244","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}